ERGO Share PerformanceMore
|52 week high||216.90 28/02/17|
|52 week low||117.00 16/09/16|
|52 week change||54.50 (37.59%)|
|4 week volume||1,005,720 28/03/17|
Latest News« previous» nextMore
13/04/2017 - 07:00 RNS
RNS Number: 3757C Ergomed plc 13 April 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Board and Management Changes London, UK - 13 April 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces Board and...
04/04/2017 - 15:30 StockMarketWire
Peter George, Non Executive Director, bought 100,000 shares in the company on the 3rd April 2017 at a price of 190.00p. The...
04/04/2017 - 10:50 RNS
RNS Number: 5275B Ergomed plc 04 April 2017 Ergomed Plc ("Ergomed" or the "Company") Director Dealing Ergomed, a profitable UK-based group dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces that on 3 April 2017, Mr Peter George, Chairman of the Company, bought 100,000 ordina...
03/04/2017 - 08:15 StockMarketWire
Ergomed has noted that co-development partner, Asarina Pharma, has today announced the publication of its phase IIa cli...
03/04/2017 - 07:00 RNS
RNS Number: 2708B Ergomed plc 03 April 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed notes co-development partner Asarina Pharma announces successful topline data for its Phase IIa Clinical Study with Sepranolone in Premenstrual Dysphoric Disorder ('PMDD') London, UK - 3 April 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Compan...
28/03/2017 - 09:54 StockMarketWire
Ergomed's revenues rose by 30% to 39.2 million in the year to the end of December and gross profit increased by 43% to 12...
28/03/2017 - 07:13 StockMarketWire
28/03/2017 - 07:00 RNS
RNS Number: 6771A Ergomed plc 28 March 2017 PRESS RELEASE EMBARGOED FOR RELEASE 7.00am 28 MARCH 2017 Unaudited Preliminary Results for the year ended 31 December 2016 Top line revenue growth of 30% Gross profit up 43% New business won in 2016 increased 50% to 42 million Contracted backlog at 1 January 2017 of 70 million Multiple co...
|Dividend yield||0 %|
Equity Research (ERGO)
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. 2016 perfectly highlighted the strengths of the...
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. The recent period end update for Ergomed confirmed...
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. It has unusually high revenue visibility, indeed...
- 1 of 2
Latest discussion posts More
“If you would like to hear management present the preliminary results for the year ended 31 December 2016 for Ergomed we will be hosting a webinar on Wednesday 29th March at ...”▼
“If you would like to hear Stephen Stamp, Chief Finance Officer, present on behalf of Ergomed he will be appearing at our next investor forum on the evening of Wednesday 25th of ...”▼
“We will be hosting a webinar with the management of Ergomed tomorrow (Tuesday 27th September) at 11.15. There will be a presentation of the interim results lasting around ...”▼
Codes & Symbols
|Symbols||ERGO, LSE:ERGO, ERGO.L, ERGO:LN, LON:ERGO, XLON:ERGO|